Acocella G, Luisetti M, Grassi G G, Peona V, Pozzi E, Grassi C
Reference Center for Chemotherapy of Mycobacterial Diseases, IRCCS San Matteo Hospital, Pavia, Italy.
Monaldi Arch Chest Dis. 1993;48(3):205-9.
A study was carried out in six human volunteers, to assess the blood kinetics of isoniazid, rifampicin and pyrazinamide, administered in a fixed-triple combination intended for use in intermittent chemotherapy of tuberculosis. The formulation employed contained 125 mg of isoniazid (H), 100 mg of rifampicin (R) and 375 mg of pyrazinamide (Z) per tablet; six tablets were administered to every subject, giving a total dosage of 750 mg of isoniazid, 600 mg of rifampicin and 2,250 mg of pyrazinamide. In each subject, the same dose of each drug was administered individually in separate sessions and the results compared. The results indicated that, at the level of dose of the intermittent tablet, no negative interactions between the drugs were observed.
在六名人类志愿者身上进行了一项研究，以评估异烟肼、利福平及吡嗪酰胺的血液动力学情况，这些药物以固定三联组合形式给药，用于肺结核的间歇化疗。所使用的制剂每片含有125毫克异烟肼（H）、100毫克利福平（R）和375毫克吡嗪酰胺（Z）；给每位受试者服用六片，异烟肼、利福平及吡嗪酰胺的总剂量分别为750毫克、600毫克和2250毫克。在每位受试者身上，每种药物相同剂量在不同时间段单独给药，并比较结果。结果表明，在间歇片剂剂量水平下，未观察到药物之间的负面相互作用。
